1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of breast cancer

LT4376848TActive Publication Date: 2026-10-26CELCUITY INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
LT4376848P0
Authority / Receiving Office
LT · LT
Patent Type
Patents
Current Assignee / Owner
Priority Date
2022-07-25
Filing Date
2022-07-25
Publication Date
2026-10-26
Estimated Expiration
2042-07-25
Patent Text Reader
Need to check novelty before this filing date? Find Prior Art
No text content released.